Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 17:81:103113.
doi: 10.1016/j.eclinm.2025.103113. eCollection 2025 Mar.

Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study

Affiliations

Cost-effectiveness of an outreach program for HCC screening in patients with cirrhosis: a microsimulation modeling study

Tami Gurley et al. EClinicalMedicine. .

Abstract

Background: Patients with cirrhosis are at high risk for hepatocellular carcinoma (HCC), but few undergo guideline-recommended semi-annual screening. Randomized clinical trials (RCTs) demonstrate that mailed outreach can increase screening versus visit-based screening. We estimated the costs and cost-effectiveness of an outreach strategy versus usual care.

Methods: We built a 10-year Markov chain Monte Carlo microsimulation model to conduct a cost-effectiveness analysis comparing a mailed outreach program versus usual care for HCC screening in a cohort of 10,000 patients with cirrhosis. Model inputs were based on literature review (2005-current), and costs were based on inflation-adjusted estimates from Surveillance, Epidemiology, and End Results (SEER)-Medicare claims data. We conducted one-way sensitivity analyses for HCC incidence, outreach costs, efficacy of the outreach strategy to increase screening, and efficacy of curative (versus palliative) HCC treatments.

Findings: Mailed outreach was estimated to cost $32.45 per patient in the first year and $21.90 per patient in subsequent years. The outreach program increased the number of HCC patients detected at an early stage by 48.4% and increased quality-adjusted life years (QALYs) by 300. Cost savings from these increases offset the costs of mailed outreach. Mailed outreach remained cost-effective across a wide range of HCC incidence rates, outreach costs, efficacy of the outreach strategy to increase screening, and the efficacy of curative HCC treatments. Annual out-of-pocket patient costs in the outreach arm were low at $13 per year.

Interpretation: Mailed outreach to encourage HCC screening in patients with cirrhosis dominates usual care and should be considered for implementation in routine practice.

Funding: National Cancer Institute and Cancer Prevention Research Institute of Texas.

Keywords: Interventions; Liver cancer; Outreach; Screening; Ultrasound.

PubMed Disclaimer

Conflict of interest statement

Amit G. Singal has served as a consultant or on advisory boards for Genentech, AztraZeneca, Eisai, Bayer, Exelixis, Elevar, Merck, Boston Scientific, Sirtex, HistoSonics, FujiFilm Medical Sciences, Exact Sciences, Roche, Glycotest, Abbott, Freenome, and GRAIL. None of the other authors have any relevant conflicts of interest.

Figures

Fig. 1
Fig. 1
Proportions of patients with early-stage HCC in mailed outreach and usual care arms. Early-stage HCC detection over 10 years is higher in the outreach arm compared to usual care.
Fig. 2
Fig. 2
One-way Sensitivity Analysis for Cost of Mailed Outreach. In one-way sensitivity analyses, mailed outreach remained cost-saving until outreach expenses exceeded $60 per patient per year.
Fig. 3
Fig. 3
One-way Sensitivity Analysis for Effectiveness of Mailed Outreach. In one-way sensitivity analyses, mailed outreach was cost savings with increases in the probability of screening >5% compared to usual care.

References

    1. Rumgay H., Arnold M., Ferlay J., et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–1606. - PMC - PubMed
    1. Llovet J.M., Kelley R.K., Villanueva A., et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. - PubMed
    1. Singal A.G., Llovet J.M., Yarchoan M., et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965. - PMC - PubMed
    1. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–422. - PubMed
    1. Singal A.G., Zhang E., Narasimman M., et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77:128–139. - PMC - PubMed

LinkOut - more resources